A61K 31/198
Alpha-amino acids
Official title: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
A61K31/198 (Alpha-amino acids) appears on 4,332 US grants and 8,646 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,332
- Published applications
- 8,646
- Assignees
- 3,067
- Inventors
- 12,106
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 15 | 0 |
| 1996 | 20 | 0 |
| 1997 | 46 | 0 |
| 1998 | 58 | 0 |
| 1999 | 66 | 0 |
| 2000 | 57 | 0 |
| 2001 | 72 | 31 |
| 2002 | 65 | 139 |
| 2003 | 84 | 213 |
| 2004 | 58 | 250 |
| 2005 | 54 | 258 |
| 2006 | 62 | 267 |
| 2007 | 61 | 244 |
| 2008 | 55 | 194 |
| 2009 | 53 | 217 |
| 2010 | 89 | 270 |
| 2011 | 97 | 263 |
| 2012 | 108 | 238 |
| 2013 | 165 | 312 |
| 2014 | 219 | 431 |
| 2015 | 197 | 424 |
| 2016 | 222 | 395 |
| 2017 | 257 | 445 |
| 2018 | 237 | 377 |
| 2019 | 258 | 429 |
| 2020 | 249 | 456 |
| 2021 | 248 | 544 |
| 2022 | 262 | 513 |
| 2023 | 229 | 499 |
| 2024 | 225 | 456 |
| 2025 | 249 | 404 |
| 2026 | 176 | 377 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Stable levothyroxine compositions in aprotic polar solvents6 Oct 2026US 12,751,937 B2Xeris Pharmaceuticals, Inc.
- Synergistic activity of novel compounds against planktonic and biofilm cells of clinically relevant pathogens6 Oct 2026US 12,752,038 B2SterileCare Inc.
- Methods of treating Prader Willi Syndrome and conditions associated with low basal metabolic rate or hyperphagia using a KATP channel opener29 Sep 2026US 12,746,244 B2Sedogen LLC
- Compounds and formulations29 Sep 2026US 12,746,248 B2Pro-Al Medico-Technologies, Inc.
- Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability29 Sep 2026US 12,746,255 B2Societe des Produits Nestle S. A.
- Tea compositions comprising paraxanthine and methods of production thereof8 Oct 2026US 2026/0305643 A1
- Perfluorocarbon compositions, systems, and methods for ischemic, inflammatory, infectuous, transplant, and other medical conditions8 Oct 2026US 2026/0306422 A1
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306431 A1Geneiii Biotech Company Ltd.
- Nutritional compositions, supplements, and fortifiers8 Oct 2026US 2026/0306432 A1Societe des Produits Nestle S. A.
- Compositions and methods for reducing blood ethanol concentration through alcohol dehydrogenase and acetaldehyde scavengers8 Oct 2026US 2026/0306589 A1Goa Therapeutics Corporation
Most cited
By later US patents
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Methods and devices for treating plumonary vasoconstriction and asthma251US 5,485,827 AThe General Hospital Corporation · 1996
- Personal safety mobile notification system229US 8,624,727 B2Saigh and Son, LLC · 2014
- Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions198US 7,048,906 B2Cedars-Sinai Medical Center · 2006
- Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors183US 6,133,320 ABoard of Regents, The University of Texas System · 2000